This application is directed to α-neuronal nicotinic receptor agonists selective for α7-subtype that are useful for improving cognition impairment in patients having schizophrenia, a schizophreniform disorder or a related schizophrenia spectrum psychotic disorder. Compounds and compositions containing such compounds, and methods of using such compound and compositions are described herein.本案係關於對α7-亞型具有選擇性之α-神經元菸鹼受體促效劑,其可用於改良患有精神分裂症、類精神分裂症性疾患或相關精神分裂症譜系精神病性疾患之患者之認知損害。本文闡述化合物,及含有該等化合物之組合物,及使用該等化合物及組合物之方法。
